Amlodipine

Excerpt

Amlodipine, an oral dihydropyridine calcium channel blocker, demonstrates prolonged efficacy by inhibiting voltage-dependent L-type calcium channels. This action interrupts initial calcium influx, distinguishing it within its pharmacological class. With a half-life of 30 to 50 hours, amlodipine affords the convenience of once-daily dosing, contrasting with shorter-acting alternatives like nifedipine. Approved as amlodipine besylate by the United States Food and Drug Administration in 1987, this medication has since become a cornerstone in managing hypertension and related conditions. This activity discusses the indications, contraindications, and nuances of amlodipine therapy essential for interprofessional collaboration. By also discussing off-label uses, monitoring protocols, and pharmacokinetic intricacies, healthcare professionals can tailor treatment regimens to individual patient needs. Armed with a comprehensive understanding of amlodipine's pharmacology, healthcare providers are empowered to optimize therapeutic outcomes while mitigating adverse effects, thereby enhancing patient care and safety.